Working… Menu

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04405739
Recruitment Status : Recruiting
First Posted : May 28, 2020
Last Update Posted : February 21, 2021
Information provided by (Responsible Party):
Ridgeback Biotherapeutics, LP

Brief Summary:
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19.

Condition or disease Intervention/treatment Phase
SARS-CoV 2 Drug: EIDD-2801 Drug: Placebo (PB0) Phase 2

Detailed Description:
Phase 2a randomized, placebo-controlled, double-blinded clinical trial of EIDD-2801 in adult men and women who have tested positive for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection within 144 hours of polymerase chain reaction (PCR) confirmation and are hospitalized with a diagnosis of COVID-19. Rapid enrollment and treatment will be initiated such that the first dose of EIDD-2801 or placebo will be administered as soon as possible and within 7 days of onset of symptoms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2
Actual Study Start Date : June 16, 2020
Estimated Primary Completion Date : May 28, 2021
Estimated Study Completion Date : May 28, 2021

Arm Intervention/treatment
Experimental: EIDD-2801 twice daily (BID) for 5 days
Dose A, Dose B, Dose C, Dose D, Dose E, Dose F
Drug: EIDD-2801
Oral capsule of EIDD-2801

Placebo Comparator: placebo (PBO) twice daily (BID) for 5 days Drug: Placebo (PB0)
Oral placebo capsule

Primary Outcome Measures :
  1. Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801 [ Time Frame: 28 days ]
    Achievement of undetectable SARS-CoV-2 RNA by Day 5 in nasopharyngeal (NP) swabs by quantitative reverse transcription polymerase chain reaction (qPCR) after administration with EIDD-2801

  2. Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS [ Time Frame: 28 days ]
    Incidence of Serious Adverse Events in subjects receiving EIDD-2801

  3. Number of Participants With any Adverse Events(AEs) as assessed by DAIDS [ Time Frame: 28 days ]
    Incidence of Adverse Events in subjects receiving EIDD-2801

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Has COVID-19 disease, defined by having one or more of the following new symptoms and signs (within 7 days):

    • Fevers OR
    • At least one of the following symptoms: cough, shortness of breath, respiratory rate ≥ 20, radiographic evidence of pneumonia OR
    • Anosmia OR
    • other clinical symptoms or signs of COVID-19 that are not otherwise explained by comorbidities or co-diagnoses
  2. PCR+ test for SARS-CoV-2.
  3. Has new signs or symptoms of COVID-19 that began ≤7 days of anticipated first dose of study drug.
  4. Persons ≥18 years old.
  5. Is admitted and is anticipated to remain in the hospital for ≥ 24 hours.
  6. Is willing and able to comply with all study procedures including providing informed consent, collection of virology samples, and any safety tests that are not included as part of standard of care (SOC).
  7. Is willing and able to take oral medications, and is anticipated to be able to take the full course of 5 days of study agent.

    Pregnancy and Contraception: Treatment with EIDD-2801 is contraindicated in women who are pregnant or nursing and in the male partners of women who are pregnant. Extreme care must be taken to avoid pregnancy during the study and for 50 days after completion of EIDD 2801 dosing in female participants and for 100 days after completion of EIDD-2801 dosing in female partners of male participants.

  8. Female participants of childbearing potential must meet the the following criteria to be enrolled:

    1. Have a negative serum pregnancy test at Screening
    2. Must agree to undergo a follow-up pregnancy test on Study Day 28.
    3. Must agree to use at least 2 forms of contraception during the study and for at least 50 days after dosing of the study drug is complete, as discussed with and approved by the investigator.

    OR Must have an azoospermic partner (vasectomized or due to a to medical cause) Note: azoospermic partner is acceptable provided that the partner is the sole sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed.

    Note that female not of childbearing potential is defined as either:

    i. Surgically sterile: females who are permanently sterile via hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy by reported medical history and/or medical records. Surgical sterilization to have occurred a minimum of 6 weeks, or at the Investigator's discretion, prior to Screening. OR

    ii. Postmenopausal: Females at least 60 years of age with amenorrhea for ≥12 months (by history) or 45 years of age with amenorrhea for 12 months without an alternative medical reason with confirmatory follicle stimulating hormone levels of ≥40 mIU/mL. The amenorrhea should not be induced by a medical condition such as anorexia nervosa, hypothyroid disease or polycystic ovarian disease, or by extreme exercise. It should not be due to concomitant medications that may have induced the amenorrhea such as oral contraceptives, hormones, gonadotropin releasing hormones, anti-estrogens, or selective estrogen receptor modulators.

  9. Male participants must refrain from donating sperm during the study and for 100 days after dosing of the study drug is complete.
  10. Male participants with female partners must have either

    1. Surgical sterilization (vasectomy ≥1 month before screening) OR
    2. Female partner must be of not be of childbearing potential OR

      • Agree to use 2 forms of contraception during the study and for 100 days after dosing of the study drug is complete, as discussed with and approved by the investigator

Exclusion Criteria:

  1. Has an illness within the past 30 days that requires mechanical ventilation prior to enrollment.
  2. Is anticipated to require ICU admission for mechanical ventilation within 24 hours of enrollment.
  3. Requires more than 6 liters/minute of oxygen to maintain O2 saturation above 95%
  4. Is not expected to survive longer than 24 hours.
  5. Has a platelet count less than 100,000/µL, hemoglobin less than 10 g/dL, or has a disorder of the hematologic system including anemic disorder or other blood dyscrasia, cancer of the hematologic system, history of bone marrow transplant, or other significant hematologic disease.
  6. Women who are pregnant or breastfeeding.
  7. Is experiencing DAIDS AE grading scale grade 4 baseline medical conditions or laboratory abnormalities..
  8. Has received an experimental vaccine for COVID-19 prior to the first dose of study drug
  9. Has received hydroxychloroquine or chloroquine within 30 days of study enrollment.
  10. Is participating in another clinical study that involves pharmacologic intervention or has participated in another study within 30 days of 5 half-lives of the investigational agent (observational study participation is permitted).
  11. In the opinion of the investigator, has end-organ disease as a result of relevant comorbidities: chronic kidney disease (reduced glomerular filtration rate (GFR) <30 mL/min by the Modification of Diet in Renal Disease (MDRD) study equation prior to COVID-19 symptom onset), decompensated chronic liver disease or cirrhosis, decompensated congestive heart failure, active peripheral vascular disease including active diabetic ulcers, chronic pulmonary disease prior to COVID-19 symptom onset requiring bilevel positive airway pressure (BiPAP) or >2 L/min supplemental oxygen at baseline; if using ≤2 L/min supplemental oxygen at baseline, consultation with and approval of the sponsor is required prior to enrollment.
  12. Has a diagnosis of cancer that is not in remission. Noninvasive cancers, such as basal and squamous cell carcinoma or history of in situ tumors are allowed at the discretion of the investigator after discussion with the sponsor.
  13. Has received an organ transplantation.
  14. Has received a bone marrow transplantation.
  15. Has been on immunosuppressive medications within one month prior to enrollment.
  16. Has any condition that would, in the opinion of the investigator, put the participant at increased risk for participation in a clinical trial.
  17. Has known active hepatitis C (HCV RNA positive), active hepatitis B (hepatitis B surface antigen positive), or HIV (ELISA and confirmatory Western blotting). New screening tests not required.
  18. Is currently taking nucleos(t)ide analogues for HIV or Hepatitis B, or for their prevention, within 30 days of study enrollment.
  19. Is currently taking systemic corticosteroids other than replacement doses, or for treatment of COVID-19.
  20. Has a Body Mass Index (BMI) >50 kg/m2.
  21. Is anticipated to require surgery within 48 hours after hospital admission.
  22. Is anticipated to have a nothing per mouth (NPO) order placed within 48 hours after hospital admission that is expected to last for > 24 hours.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04405739

Layout table for location contacts
Contact: Laura Szewczyk 786-687-2495

Layout table for location information
United States, California
Ronald Reagan UCLA Medical Center Recruiting
Los Angeles, California, United States, 90095-8358
Contact: Chen "Anna" Zheng    310-794-0129   
Principal Investigator: Debika Bhattacharya, MD         
United States, Illinois
Cook County Hospital Not yet recruiting
Chicago, Illinois, United States, 60612
Contact: Mathew Itteera    312-864-4606      
Advocate Christ Medical Center Recruiting
Oak Lawn, Illinois, United States, 60453
Contact: Adam Treitman, MD    847-723-8200      
Advocate Lutheran General Hospital Recruiting
Park Ridge, Illinois, United States, 60068
Contact: Adam Treitman, MD    847-723-8200      
United States, Maryland
Johns Hopkins Bayview Medical Center Recruiting
Baltimore, Maryland, United States, 21224
Contact: Stephanie Swords   
Principal Investigator: Ashwan Balagopal         
John Hopkins Hospital Recruiting
Baltimore, Maryland, United States, 21287
Contact: Stephanie Swords   
Principal Investigator: Ashwin Balagopal         
Suburban Hospital Recruiting
Bethesda, Maryland, United States, 20814
Contact: Stephanie Swords   
Principal Investigator: Ashwin Balagopal         
Howard County General Hospital Recruiting
Columbia, Maryland, United States, 21044
Contact: Stephanie Swords   
Principal Investigator: Ashwin Balagopal         
United States, North Carolina
Wake Forest Baptist Health Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Elizabeth Zieser-Misenheimer   
Principal Investigator: Caryn Morse, MD         
United States, Tennessee
Vanderbilt University Recruiting
Nashville, Tennessee, United States, 37235
Contact: Todd Rice, MD         
United States, Texas
Houston Methodist Hospital Recruiting
Houston, Texas, United States, 77030
Contact: Krystin Nieto    713-441-3192      
Principal Investigator: Daniela Moran, MD         
Sponsors and Collaborators
Ridgeback Biotherapeutics, LP
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ridgeback Biotherapeutics, LP Identifier: NCT04405739    
Other Study ID Numbers: EIDD-2801-2004
First Posted: May 28, 2020    Key Record Dates
Last Update Posted: February 21, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No